Every 10-Q that Labcorp Holdings Inc. (LH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LH filings page.
Labcorp Holdings Inc. reported first-quarter 2026 revenues of $3,537.6 million, up 5.8% from 2025, driven by 3.1% organic growth, acquisitions, and favorable currency. Diagnostics Laboratories contributed $2,762.1 million (5.0% growth) and Biopharma Laboratory Services $780.6 million (8.2% growth).
Net earnings attributable to Labcorp rose to $277.8 million from $212.8 million, with diluted EPS increasing to $3.35 from $2.52. Cost of revenues fell slightly as a percentage of sales and SG&A leveraged on higher revenue, supporting operating income of $380.8 million.
Operating cash flow improved sharply to $191.5 million. The company spent $202.2 million on acquisitions, including Empire City Laboratories, and repurchased 0.4 million shares for $98.0 million. It ended the quarter with $981.1 million in cash, a new $750.0 million term loan, ongoing share repurchase authorization, and a quarterly dividend of $0.72 per share.
Labcorp Holdings Inc. reported stronger Q3 results. Revenue rose to $3,563.5 million from $3,282.0 million a year ago, and diluted EPS increased to $3.12 from $2.00 as operating income improved to $396.6 million. Diagnostics contributed about 78% of revenue and Biopharma Laboratory Services about 22%.
Year to date, revenue reached $10,435.9 million with net earnings attributable to Labcorp of $711.8 million. Cash from operations was strong at $1,026.3 million, supporting capital spending and portfolio moves. The company deployed $324.0 million on acquisitions and repurchased 0.9 million shares for $225.0 million at an average of $249.27. A quarterly dividend of $0.72 per share continued.
Balance sheet highlights show cash of $598.1 million, total assets of $18,261.6 million, and total debt of $5,582.4 million including the current portion. The accounts receivable securitization facility was increased to $700.0 million with $525.0 million outstanding. The company also announced agreements to acquire CHS outreach assets for approximately $195.0 million and Empire City Laboratories for up to $250.0 million, pending approvals.